These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 7715015

  • 1. Immunotherapy of an experimental adenocarcinoma of the prostate.
    Morales A, Nickel JC, Downey J, Clark J, van der Linden I.
    J Urol; 1995 May; 153(5):1706-10. PubMed ID: 7715015
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.
    Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B, Gilboa E.
    Cancer Res; 1994 Apr 01; 54(7):1760-5. PubMed ID: 8137291
    [Abstract] [Full Text] [Related]

  • 3. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
    Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS.
    Urology; 1997 Dec 01; 50(6):999-1006. PubMed ID: 9426741
    [Abstract] [Full Text] [Related]

  • 4. Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats.
    Chen WR, Liu H, Ritchey JW, Bartels KE, Lucroy MD, Nordquist RE.
    Cancer Res; 2002 Aug 01; 62(15):4295-9. PubMed ID: 12154032
    [Abstract] [Full Text] [Related]

  • 5. In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327.
    Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A.
    Cancer Res; 1992 Nov 15; 52(22):6353-7. PubMed ID: 1423282
    [Abstract] [Full Text] [Related]

  • 6. Administration of recombinant tumor necrosis factor to rats bearing the Dunning R3327 MAT-LyLu prostatic adenocarcinoma.
    Shaw MW, Guinan PD, Dubin A, McKiel CF, Rubenstein M.
    Clin Physiol Biochem; 1987 Nov 15; 5(6):315-9. PubMed ID: 3446431
    [Abstract] [Full Text] [Related]

  • 7. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder.
    Morales A, Chin JL, Ramsey EW.
    J Urol; 2001 Nov 15; 166(5):1633-7; discussion 1637-8. PubMed ID: 11586191
    [Abstract] [Full Text] [Related]

  • 8. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D, Tiserová H, Fucíková J, Last'ovicka J, Podrazil M, Ulcová H, Budínský V, Prausová J, Linke Z, Minárik I, Sedivá A, Spísek R, Bartůnková J.
    Clin Immunol; 2009 Apr 15; 131(1):1-10. PubMed ID: 19201656
    [Abstract] [Full Text] [Related]

  • 9. Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth.
    Hautmann SH, Huland E, Huland H.
    Anticancer Res; 1999 Apr 15; 19(4A):2661-3. PubMed ID: 10470215
    [Abstract] [Full Text] [Related]

  • 10. Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from Dunning prostatic adenocarcinoma challenge.
    Friedman EJ, Orth CR, Brewton KA, Ponniah S, Alexander RB.
    J Urol; 1997 Oct 15; 158(4):1585-8. PubMed ID: 9302178
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

  • 12. Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model.
    Johannsen M, Thiesen B, Jordan A, Taymoorian K, Gneveckow U, Waldöfner N, Scholz R, Koch M, Lein M, Jung K, Loening SA.
    Prostate; 2005 Aug 01; 64(3):283-92. PubMed ID: 15726645
    [Abstract] [Full Text] [Related]

  • 13. Immunotherapy by BCG against prostate adenocarcinomas in anatomical compartments.
    Pollard M, Luckert PH.
    Anticancer Res; 1994 Aug 01; 14(6B):2691-4. PubMed ID: 7872703
    [Abstract] [Full Text] [Related]

  • 14. Effect of the preestrogen 4-androstene-3,17-dion-19-al on the Dunning R3327 prostatic adenocarcinoma.
    Marks TA, Petrow V.
    Cancer Res; 1983 Aug 01; 43(8):3687-90. PubMed ID: 6861138
    [Abstract] [Full Text] [Related]

  • 15. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 16. A high-fat diet does not influence the growth of the Dunning R3327-H transplantable prostate adenocarcinoma.
    Schwab ED, Normolle D, Pacis RA, Cho SS, Pienta KJ.
    Anticancer Res; 1998 May 15; 18(5A):3603-7. PubMed ID: 9858946
    [Abstract] [Full Text] [Related]

  • 17. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C, Sanda MG.
    Curr Opin Mol Ther; 1999 Aug 15; 1(4):471-9. PubMed ID: 11713762
    [Abstract] [Full Text] [Related]

  • 18. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors.
    Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL.
    Gene Ther; 1998 Oct 15; 5(10):1400-9. PubMed ID: 9930346
    [Abstract] [Full Text] [Related]

  • 19. Tumor prevention and antitumor immunity with heat shock protein 70 induced by 15-deoxy-delta12,14-prostaglandin J2 in transgenic adenocarcinoma of mouse prostate cells.
    Vanaja DK, Grossmann ME, Celis E, Young CY.
    Cancer Res; 2000 Sep 01; 60(17):4714-8. PubMed ID: 10987274
    [Abstract] [Full Text] [Related]

  • 20. [Potentiation of focal ultrasound treatment of prostate adenocarcinoma by concomitant chemotherapy with estramustine phosphate and paclitaxel].
    Paparel P, Chapelon JY, Curiel L, Rabilloud M, Chesnais S, Gelet A.
    Prog Urol; 2004 Feb 01; 14(1):40-6. PubMed ID: 15098750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.